The eMap-Coronavirus2019

EU RESEARCH AND INNOVATION

Vaccines

​​This Interactive Neural eMap offers an updated mapping of new and ongoing EU Research Projects, initiatives and news related to Coronavirus Vaccine Research.

 

Outline show/hide

EU RESPONSE TO COVID-19

Research & Innovation Projects
VACCINES

CUREVAC (D)

RNA based vaccine for coronavirus
€75 million in financing was offered to CureVac, an innovative vaccines company with a potential messenger RNA based vaccine for coronavirus. The funding comes from the European Investment Bank (EIB) working in collaboration with the European Commission, through the InnovFin financing mechanism, and will help accelerate development of a vaccine.

In 2014 CureVac received the first ever EU innovation inducement prize of €2 million.

• Testimonial: Lidia Oostvogels (Area head infectious diseases at Curevac)

• Story: Five things you need to know about: mRNA vaccines

INFO

DIVINE

Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies: higher purity, faster and cheaper with novel affinity ligands and biomimetic membranes. Led by Instituto de Biologia Experimental e Tecnológica – IBET (PT).

• DiViNe website

• Project details

GAVI

The vaccine Alliance of Bill and Melinda Gates Foundation.
€200 million from EU Commission

WEBSITE

MYCOSYNVAC (ES)

Engineering of Mycoplasma pneumoniae as a broad-spectrum animal vaccine.

• MycoSynVac website

• Project details

• Project video game

OPENCORONA (SE)

Rapid therapy development through Open Coronavirus Vaccine Platform.

• Project details

• Story: Three KI-led coronavirus projects selected in EU funding round

• Testimonial: Matti Sällberg (Head of Department of Laboratory Medicine, Karolinska Institute, Stockholm)

NEWCOTIANA

Breeding new plant biofactories

Genome editing and other new breeding techniques to adapt tobacco plants as biofactories for health-related bioproducts, such as vaccines, and antibodies.

• Newcotiana website

• Project details

PREVENT-NCOV (DK)

Prevention of 2019 nCoV infection through development and clinical testing of a novel Virus Like Particle (VLP) vaccine to expose coronavirus proteins to the immune system.

• Project details

• Story: Manufacturing agreement with AGC biologics accelerates COVID-19 vaccine program

• Testimonial from Morten Nielsen (Departement of immunology and microbiology, University of Copenhagen)

• Futuris video: Europe supercharges research in the battle against COVID-19

TRANSVAC2

The EU vaccine R&D infrastructure that offers researchers a wide range of technical vaccine development services at no cost in most cases. Budget: €20.5 million since 2009.

• Project website

• Project details

• Call for applications

Go to the online App